The new standalone company is worth up to 28 billion Swiss francs.In November 2021, Alcon announced it would acquire Ivantis and their glaucoma surgery stent technology for at least $475 million. In August 2022, Alcon agreed to buy Aerie Pharmaceuticals for US$770 million to enhance its ophthalmic pharmaceutical portfolio. References
External links

Business data for Alcon: 
Alcon Official Website
Alcon : Novartis exercises option and proposes merger
Novartis needs Alcon directors OK for buyout
Swiss Corporate Governance Expert Supports Alcon Independent Director Committee’s Position against Novartis
Other methods
By simply not stimulating the breasts after birth, after a few days the production of milk will decease. If breastfeeding has already been established, the production of milk typically takes longer to decrease and may take several weeks. Women may experience pain and discomfort from engorgement. This discomfort is may be relieved by hand-expressing milk or the use of a pump to reduce engorgement and prevent mastitis. The discomfort can also be treated with analgesics. However, as much as one third of all women will experience severe pain in this process.Historically, binding the breasts by use of tight-fitting bras or ace bandages was used, but this is now discouraged as this may cause blocked milk ducts and mastitis. Fluid restriction is also not recommended as it is likely ineffective and unnecessary.Cabbage leaves are a common recommendation to reduce discomfort from engorgement. However, a Cochrane review of three studies on this subject concluded that there was no statistically significant evidence that interventions were associated with a more rapid resolution of symptoms; in these studies women tended to have improvements in pain and other symptoms over time whether or not they received active treatment.According to the Cochrane review other interventions such as hot/cold packs, Gua-Sha (scraping therapy), acupuncture, and proteolytic enzymes may be promising for the treatment of breast engorgement, but there is insufficient evidence to justify widespread implementation. See also
Hypothalamic–pituitary–prolactin axis
Prolactin modulator


== References ==